Skip to main content
Erschienen in: European Radiology 4/2021

01.10.2020 | Hepatobiliary-Pancreas

The Liver Imaging Reporting and Data System tumor-in-vein category: a systematic review and meta-analysis

verfasst von: Dong Hwan Kim, Sang Hyun Choi, Seong Ho Park, Kyung Won Kim, Jae Ho Byun, So Yeon Kim, Seung Soo Lee, Joon-Il Choi

Erschienen in: European Radiology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

We aimed to systematically determine the etiology of the Liver Imaging Reporting and Data System (LI-RADS) tumor-in-vein category (LR-TIV) on contrast-enhanced CT or MRI and to determine the sources of heterogeneity between reported results.

Methods

Original studies reporting the etiology of LR-TIV were identified in MEDLINE and EMBASE up until July 7, 2020. The meta-analytic pooled percentages of HCC and non-HCC in LR-TIV were calculated. Subgroup analyses were performed according to the type of reference standard and the most common underlying liver disease. Meta-regression analysis was performed to explore study heterogeneity.

Results

Sixteen studies reported the etiology of a total of 150 LR-TIV, of which 98 (65%) were HCC and 52 (35%) were non-HCC. The meta-analytic pooled percentages of HCC and non-HCC in LR-TIV were 70.9% (95% confidence interval [CI], 55.7–82.5%; I2 = 59%) and 29.2% (95% CI, 17.5–44.4%; I2 = 59%), respectively. The meta-analytic pooled percentage of HCC was lower in studies using only pathology as a reference standard (67.1%; 95% CI, 49.3–81.1%), but higher in studies in which hepatitis C was the most common underlying liver disease (81.9%; 95% CI, 11.3–99.4%) than that in the total 16 studies. Study type (cohort study versus case-control study) was significantly associated with study heterogeneity (p = 0.04).

Conclusion

The most common etiology of LR-TIV was HCC. It might be important to understand the percentage of HCC and non-HCC in LR-TIV in consideration of the type of reference standard, geographic differences, and study design.

Key Points

• The most common etiology of Liver Imaging Reporting and Data System (LI-RADS) tumor-in-vein category (LR-TIV) was hepatocellular carcinoma (HCC).
• The percentage of HCC in LR-TIV was relatively low in studies using only pathology as a reference standard, but high in studies in which hepatitis C was the most common underlying liver disease.
• Study type was a factor significantly influencing study heterogeneity.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Mitchell DG, Bruix J, Sherman M, Sirlin CB (2015) LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology 61:1056–1065CrossRef Mitchell DG, Bruix J, Sherman M, Sirlin CB (2015) LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology 61:1056–1065CrossRef
3.
Zurück zum Zitat Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR (2018) LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol (NY) 43:149–157CrossRef Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR (2018) LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol (NY) 43:149–157CrossRef
4.
Zurück zum Zitat Roayaie S, Blume IN, Thung SN et al (2009) A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 137:850–855CrossRef Roayaie S, Blume IN, Thung SN et al (2009) A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 137:850–855CrossRef
5.
Zurück zum Zitat Doussot A, Lim C, Gomez-Gavara C et al (2016) Multicentre study of the impact of morbidity on long-term survival following hepatectomy for intrahepatic cholangiocarcinoma. Br J Surg 103:1887–1894CrossRef Doussot A, Lim C, Gomez-Gavara C et al (2016) Multicentre study of the impact of morbidity on long-term survival following hepatectomy for intrahepatic cholangiocarcinoma. Br J Surg 103:1887–1894CrossRef
6.
Zurück zum Zitat van der Pol CB, Lim CS, Sirlin CB et al (2019) Accuracy of the liver imaging reporting and data system in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy-a systematic review. Gastroenterology 156:976–986CrossRef van der Pol CB, Lim CS, Sirlin CB et al (2019) Accuracy of the liver imaging reporting and data system in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy-a systematic review. Gastroenterology 156:976–986CrossRef
7.
Zurück zum Zitat Lee SM, Lee JM, Ahn SJ, Kang HJ, Yang HK, Yoon JH (2019) LI-RADS version 2017 versus version 2018: diagnosis of hepatocellular carcinoma on gadoxetate disodium-enhanced MRI. Radiology 292:655–663CrossRef Lee SM, Lee JM, Ahn SJ, Kang HJ, Yang HK, Yoon JH (2019) LI-RADS version 2017 versus version 2018: diagnosis of hepatocellular carcinoma on gadoxetate disodium-enhanced MRI. Radiology 292:655–663CrossRef
8.
Zurück zum Zitat Ren AH, Zhao PF, Yang DW, Du JB, Wang ZC, Yang ZH (2019) Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017. J Magn Reson Imaging 50:746–755CrossRef Ren AH, Zhao PF, Yang DW, Du JB, Wang ZC, Yang ZH (2019) Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017. J Magn Reson Imaging 50:746–755CrossRef
9.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700CrossRef Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700CrossRef
10.
Zurück zum Zitat Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529–536CrossRef Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529–536CrossRef
11.
Zurück zum Zitat Alhasan A, Cerny M, Olivie D et al (2019) LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Abdom Radiol (NY) 44:517–528CrossRef Alhasan A, Cerny M, Olivie D et al (2019) LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Abdom Radiol (NY) 44:517–528CrossRef
12.
Zurück zum Zitat Choi SH, Lee SS, Park SH et al (2019) LI-RADS classification and prognosis of primary liver cancers at gadoxetic acid-enhanced MRI. Radiology 290:388–397CrossRef Choi SH, Lee SS, Park SH et al (2019) LI-RADS classification and prognosis of primary liver cancers at gadoxetic acid-enhanced MRI. Radiology 290:388–397CrossRef
13.
Zurück zum Zitat Jeon SK, Joo I, Lee DH et al (2019) Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol 29:373–382CrossRef Jeon SK, Joo I, Lee DH et al (2019) Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol 29:373–382CrossRef
14.
Zurück zum Zitat Joo I, Lee JM, Lee DH, Jeon JH, Han JK (2019) Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features? Eur Radiol 29:1724–1732CrossRef Joo I, Lee JM, Lee DH, Jeon JH, Han JK (2019) Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features? Eur Radiol 29:1724–1732CrossRef
15.
Zurück zum Zitat Kierans AS, Makkar J, Guniganti P et al (2019) Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) criteria for imaging diagnosis of hepatocellular carcinoma. J Magn Reson Imaging 49:e205–e215CrossRef Kierans AS, Makkar J, Guniganti P et al (2019) Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) criteria for imaging diagnosis of hepatocellular carcinoma. J Magn Reson Imaging 49:e205–e215CrossRef
16.
Zurück zum Zitat Kim DH, Choi SH, Byun JH et al (2019) Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma. J Hepatol 71:534–542CrossRef Kim DH, Choi SH, Byun JH et al (2019) Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma. J Hepatol 71:534–542CrossRef
17.
Zurück zum Zitat Ludwig DR, Fraum TJ, Cannella R et al (2019) Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018. Abdom Radiol (NY) 44:2116–2132CrossRef Ludwig DR, Fraum TJ, Cannella R et al (2019) Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018. Abdom Radiol (NY) 44:2116–2132CrossRef
18.
Zurück zum Zitat Seo N, Kim MJ, Rhee H (2019) Hepatic sarcomatoid carcinoma: magnetic resonance imaging evaluation by using the liver imaging reporting and data system. Eur Radiol 29:3761–3771CrossRef Seo N, Kim MJ, Rhee H (2019) Hepatic sarcomatoid carcinoma: magnetic resonance imaging evaluation by using the liver imaging reporting and data system. Eur Radiol 29:3761–3771CrossRef
19.
Zurück zum Zitat Zhang T, Huang ZX, Wei Y et al (2019) Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy? World J Gastroenterol 25:622–631CrossRef Zhang T, Huang ZX, Wei Y et al (2019) Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy? World J Gastroenterol 25:622–631CrossRef
24.
25.
Zurück zum Zitat Nohr EA, Liew Z (2018) How to investigate and adjust for selection bias in cohort studies. Acta Obstet Gynecol Scand 97:407–416CrossRef Nohr EA, Liew Z (2018) How to investigate and adjust for selection bias in cohort studies. Acta Obstet Gynecol Scand 97:407–416CrossRef
26.
Zurück zum Zitat Sasaki K, Margonis GA, Andreatos N et al (2018) Preoperative risk score and prediction of long-term outcomes after hepatectomy for intrahepatic cholangiocarcinoma. J Am Coll Surg 226:393–403CrossRef Sasaki K, Margonis GA, Andreatos N et al (2018) Preoperative risk score and prediction of long-term outcomes after hepatectomy for intrahepatic cholangiocarcinoma. J Am Coll Surg 226:393–403CrossRef
27.
Zurück zum Zitat Wu D, Shen ZY, Zhang YM et al (2015) Effect of liver transplantation in combined hepatocellular and cholangiocellular carcinoma: a case series. BMC Cancer 15:232CrossRef Wu D, Shen ZY, Zhang YM et al (2015) Effect of liver transplantation in combined hepatocellular and cholangiocellular carcinoma: a case series. BMC Cancer 15:232CrossRef
28.
Zurück zum Zitat Wakizaka K, Yokoo H, Kamiyama T et al (2019) Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers. J Gastroenterol Hepatol 34:1074–1080CrossRef Wakizaka K, Yokoo H, Kamiyama T et al (2019) Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers. J Gastroenterol Hepatol 34:1074–1080CrossRef
Metadaten
Titel
The Liver Imaging Reporting and Data System tumor-in-vein category: a systematic review and meta-analysis
verfasst von
Dong Hwan Kim
Sang Hyun Choi
Seong Ho Park
Kyung Won Kim
Jae Ho Byun
So Yeon Kim
Seung Soo Lee
Joon-Il Choi
Publikationsdatum
01.10.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 4/2021
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-020-07282-x

Weitere Artikel der Ausgabe 4/2021

European Radiology 4/2021 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.